RS56509B1 - Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline - Google Patents

Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline

Info

Publication number
RS56509B1
RS56509B1 RS20171063A RSP20171063A RS56509B1 RS 56509 B1 RS56509 B1 RS 56509B1 RS 20171063 A RS20171063 A RS 20171063A RS P20171063 A RSP20171063 A RS P20171063A RS 56509 B1 RS56509 B1 RS 56509B1
Authority
RS
Serbia
Prior art keywords
dihydro
compound
salt
benzoxazol
methyl
Prior art date
Application number
RS20171063A
Other languages
English (en)
Serbian (sr)
Inventor
Britta Olenik
Birgit Keil
Martin Holger Hinz
Chantal Fürstner
Mario Jeske
Jens Ackerstaff
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of RS56509B1 publication Critical patent/RS56509B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RS20171063A 2013-11-08 2014-11-05 Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline RS56509B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192177 2013-11-08
PCT/EP2014/073801 WO2015067652A1 (de) 2013-11-08 2014-11-05 Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure
EP14793565.4A EP3066097B1 (de) 2013-11-08 2014-11-05 Salze von 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure

Publications (1)

Publication Number Publication Date
RS56509B1 true RS56509B1 (sr) 2018-02-28

Family

ID=49552231

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171063A RS56509B1 (sr) 2013-11-08 2014-11-05 Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline

Country Status (32)

Country Link
US (1) US9926305B2 (enExample)
EP (1) EP3066097B1 (enExample)
JP (1) JP6446051B2 (enExample)
KR (1) KR102351418B1 (enExample)
CN (1) CN105658647B (enExample)
AP (1) AP2016009181A0 (enExample)
AU (1) AU2014345599B2 (enExample)
BR (1) BR112016010253A8 (enExample)
CA (1) CA2929780C (enExample)
CL (1) CL2016001096A1 (enExample)
CY (1) CY1119520T1 (enExample)
DK (1) DK3066097T3 (enExample)
EA (1) EA033132B1 (enExample)
ES (1) ES2645480T3 (enExample)
HR (1) HRP20171603T1 (enExample)
HU (1) HUE035021T2 (enExample)
IL (1) IL245407B (enExample)
LT (1) LT3066097T (enExample)
MA (1) MA39020A1 (enExample)
ME (1) ME02907B (enExample)
MX (1) MX366848B (enExample)
MY (1) MY190108A (enExample)
NO (1) NO3066097T3 (enExample)
PH (1) PH12016500853B1 (enExample)
PL (1) PL3066097T3 (enExample)
PT (1) PT3066097T (enExample)
RS (1) RS56509B1 (enExample)
SA (1) SA516371082B1 (enExample)
SI (1) SI3066097T1 (enExample)
TN (1) TN2016000170A1 (enExample)
UA (1) UA117686C2 (enExample)
WO (1) WO2015067652A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3338780A1 (de) 2016-12-20 2018-06-27 Bayer Pharma Aktiengesellschaft Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind
CA3061444A1 (en) * 2017-04-27 2018-11-01 Bayer Aktiengesellschaft Selective adrenoreceptor .alpha.2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad)
WO2022135502A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 多取代的尿嘧啶衍生物及其用途
TW202404601A (zh) * 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032881A1 (en) * 2000-10-19 2002-04-25 Nippon Kayaku Kabushiki Kaisha Novel remedies or preventives for angiostenosis
AT511788A1 (de) 2011-07-29 2013-02-15 Georg Dr Gaul Vorrichtung zur vorgebbaren anordnung eines stents
CA2866184A1 (en) * 2012-03-05 2013-09-12 Gratuk Technologies Pty Ltd Dietary supplement
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
CA2929763A1 (en) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors

Also Published As

Publication number Publication date
LT3066097T (lt) 2018-02-12
MY190108A (en) 2022-03-29
BR112016010253A2 (pt) 2017-08-08
HUE035021T2 (en) 2018-03-28
NO3066097T3 (enExample) 2018-01-13
AU2014345599A1 (en) 2016-05-19
KR102351418B1 (ko) 2022-01-17
CY1119520T1 (el) 2018-03-07
JP2016535096A (ja) 2016-11-10
EA033132B1 (ru) 2019-08-30
JP6446051B2 (ja) 2018-12-26
HRP20171603T1 (hr) 2017-12-01
CN105658647A (zh) 2016-06-08
MX2016005971A (es) 2016-08-11
US9926305B2 (en) 2018-03-27
EA201600381A1 (ru) 2016-10-31
MA39020A1 (fr) 2017-04-28
ME02907B (me) 2018-04-20
PH12016500853B1 (en) 2021-03-24
HK1222171A1 (zh) 2017-06-23
PH12016500853A1 (en) 2016-06-20
CA2929780A1 (en) 2015-05-14
AP2016009181A0 (en) 2016-04-30
CL2016001096A1 (es) 2016-12-23
SI3066097T1 (sl) 2017-12-29
IL245407B (en) 2019-10-31
US20160289220A1 (en) 2016-10-06
DK3066097T3 (da) 2017-11-06
TN2016000170A1 (en) 2017-10-06
MX366848B (es) 2019-07-26
WO2015067652A1 (de) 2015-05-14
AU2014345599B2 (en) 2019-02-14
KR20160078980A (ko) 2016-07-05
BR112016010253A8 (pt) 2021-06-22
SA516371082B1 (ar) 2019-05-16
PT3066097T (pt) 2017-11-10
NZ719532A (en) 2021-06-25
UA117686C2 (uk) 2018-09-10
ES2645480T3 (es) 2017-12-05
IL245407A0 (en) 2016-06-30
EP3066097A1 (de) 2016-09-14
EP3066097B1 (de) 2017-08-16
PL3066097T3 (pl) 2018-01-31
CN105658647B (zh) 2019-09-06
CA2929780C (en) 2022-03-22

Similar Documents

Publication Publication Date Title
TWI304062B (en) N-(pyridin-2-yl)-sulfonamide derivatives
US8455484B2 (en) Selected inhibitors of protein tyrosine kinase activity
CN117045653A (zh) 与毒性醛相关的疾病和治疗
US20190322625A1 (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof
RS56509B1 (sr) Soli 1-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-6-il)-2,4-diokso-3-[(1r)-4-trifluorometil)-2,3-dihidro-1h-inden-1-il]-1,2,3,4-tetrahidropirimidin-5-karboksilne kiseline
JP2019524710A5 (enExample)
EP3759095A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
AU2007230948B2 (en) Modified macrophage migration inhibitory factor inhibitors
HK1222171B (zh) 化合物的盐
CN116806150A (zh) 新的自分泌运动因子抑制剂
NZ719532B2 (en) Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid
CN104768927A (zh) (3s,3s’)-4,4’-二硫烷二基双(3-氨基丁烷-1-磺酸)合l-赖氨酸的新的结晶相
CN110003117B (zh) 一种含三氟甲基嘧啶的阿魏酸酰胺衍生物及其制备和用途
CN116178435A (zh) 一种1,-腈基取代核苷衍生物及其用途
CN120774918A (zh) 蛋白降解剂类化合物及其制备方法、药物组合物和应用
EP1604976A1 (en) Nimesulide derivative method for its preparation and a pharmaceutical composition containing the same
JP2012512206A (ja) 4−({(4−カルボキシブチル)[2−(2−{[4−(2−フェニルエチル)ベンジル]オキシ}フェニル)エチル]−アミノ}メチル)安息香酸の一水和物
JP2012512204A (ja) 4−({(4−カルボキシブチル)[2−(2−{[4−(2−フェニルエチル)ベンジル]オキシ}フェニル)エチル]アミノ}メチル)安息香酸の変態i
HK1078562B (en) Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
HK1107263A1 (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
HK1107263B (en) Non-peptide bradykinin antagonists and pharmaceutical compositions therefrom